Head and Neck Squamous Cell Carcinoma
Fondazione GONO Plus is active in head and neck oncology, with studies spanning recurrent/metastatic HNSCC, HPV-negative HNSCC, and locally advanced oral cavity squamous cell carcinoma. The research portfolio reflects a strong interest in treatment strategies for advanced disease settings and biomarker-defined patient groups.
- Recurrent/metastatic HNSCC
- HPV-negative head and neck cancer
- Oral cavity squamous cell carcinoma
The sponsor’s work in this area includes investigation of immunotherapy, platinum-based chemotherapy, and combination approaches used in advanced squamous tumours of the upper aerodigestive tract.
Immuno-Oncology
A major area of interest is immuno-oncology, particularly in combination regimens for difficult-to-treat solid tumours. The funded trials include therapies involving PD-L1-directed treatment, anti-EGFR therapy, and other immune-based strategies in advanced head and neck malignancies.
- PD-L1-related treatment strategies
- Checkpoint inhibitor combinations
- Immune-based maintenance therapy
This area also covers sequence-based treatment approaches designed for patients with limited options after prior systemic therapy.
Targeted Therapy and DNA Repair
The sponsor supports research in targeted oncology with emphasis on PARP inhibition and other pathway-focused strategies. These studies address tumours in which DNA repair and molecularly guided treatment may influence therapeutic response.
- PARP inhibitor-based regimens
- Biomarker-selected therapy
- Molecularly guided treatment
Trial activity in this domain includes combinations pairing targeted agents with immunotherapy in advanced head and neck cancer and related solid tumours.
Skin Cancer
Fondazione GONO Plus also funds research in locally advanced basal cell carcinoma, with interest in Hedgehog pathway inhibition and treatment scheduling after tumour response. This reflects attention to non-melanoma skin cancer management in advanced disease.
- Basal cell carcinoma
- Hedgehog pathway inhibition
- Advanced skin cancer treatment
The portfolio includes clinical research focused on maintaining disease control in patients with locally advanced BCC.
Nasopharyngeal Cancer
The sponsor is involved in studies for recurrent/metastatic, platinum-resistant nasopharyngeal cancer, highlighting an interest in aggressive disease with limited standard options. This area includes combined use of immunotherapy and targeted agents in nasopharyngeal carcinoma.
- Platinum-resistant nasopharyngeal cancer
- Recurrent/metastatic disease
- Combination systemic therapy
Research in this field aligns with broader efforts in advanced head and neck malignancies requiring novel therapeutic approaches.
